Grifols S.A. ADR Stock
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Grifols S.A. ADR | - | -4.969% | 2.000% | -12.069% | -17.297% | -40.290% | -58.210% |
Cellectar BioSciences Inc. | 0.580% | -5.263% | -4.255% | -22.414% | -21.053% | -78.313% | - |
Beximco Pharmaceuticals Ltd. GDR | 2.340% | 4.918% | -15.789% | -39.623% | -41.818% | -76.727% | -32.632% |
SELLAS Life Sciences Group Inc | -1.060% | -1.439% | -7.119% | -25.846% | 12.410% | -87.517% | -80.341% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "sell" rating.
Show more
Ratings data for GRFS provided by MarketBeat